Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CPHD - Cephid -- Ignore unavailable to you. Want to Upgrade?

To: jmhollen who wrote (1)	4/11/2002 6:40:35 PM
From: Ron	Respond to of 8

*DJ Cepheid Gets Two US Patents Covering I-CORE DNA Detection DJ Cepheid/Patents -2: Detects Up To 4 Nucleic Acids - SUNNYVALE, Calif. (Dow Jones)--Cepheid (CPHD) received two U.S. patents covering its I-CORE module technology for DNA detection and the automated preparation of biological samples using chip-based microfluidics technology. In a press release Thursday, the biotechnology company said the I-CORE module, a key component in Cepheid's DNA testing and analysis systems, has an optical analysis system which can excite and detect up to four nucleic acids simultaneously. Cepheid has 36 U.S. patents issued or pending, plus corresponding foreign patent applications. Cepheid, developing and marketing integrated systems for DNA detection, had revenue of $11.4 million in 2001. The company's shares closed Thursday on Nasdaq at $3.70, up 41 cents, or 12.5%, on volume of 749,200 shares. Average daily trade volume is 593,498 shares. Company Web Site: cepheid.com

To: jmhollen who wrote (1)	4/15/2002 5:23:09 PM
From: Ron	Respond to of 8

CPHD hires a pro: SUNNYVALE, Calif., April 15 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD) today announced that John L. Bishop, formerly president and CEO of Vysis Inc., now a wholly-owned clinical diagnostics subsidiary of Abbott Laboratories (NYSE: ABT), has joined the company as chief executive officer and a member of the board of directors. He succeeds co-founder Thomas L. Gutshall who will continue as chairman. "Clinical diagnostics represents a major untapped opportunity for Cepheid's DNA testing products, and John's outstanding record of success in creating and expanding new markets will be a tremendous asset," said Gutshall. "I am very proud of our achievements and believe his addition to our executive team well positions Cepheid to dramatically impact this and other segments of the DNA testing market." "I am pleased to have the opportunity to become a member of Cepheid's executive team. The company's technology and products have the potential to bring the full benefit of genomic information to the medical community on the broadest possible basis," said Bishop. "The ability to obtain results of DNA analyses in 30 minutes or less will allow the clinician to take full advantage of this information to diagnose and treat disease." Bishop brings more than 25 years of management experience in instrumentation and clinical diagnostics. His most recent achievement was in creating Vysis, a genomic disease management company, from assets of the Diagnostic Sector of Amoco Technology Company. The company grew from a developer and marketer of life-science research products to a provider of clinical diagnostics, notably the PathVysion(R) HER-2 Test for selecting breast cancer patients for Herceptin(R) therapy. Bishop took the company public in 1998 and was subsequently involved in its sale to Abbott Laboratories in December of 2001 for a valuation of approximately $355 million. Cepheid, based in Sunnyvale, Calif., is a leading developer, manufacturer and marketer of miniaturized, fully integrated systems for rapid, on-site detection of DNA -- the universal biological identifier. Founded in 1996, the company is commercializing its technology and products for scientific, medical and industrial applications requiring time-critical detection of human and other genes, infectious disease agents, and industrial and environmental contaminants at the point of need. See cepheid.com for more information. NOTE: Herceptin(R) is a registered trademark of Genentech, Inc. PathVysion(R) is a registered trademark of Abbott Laboratories. Statements in this release, including those that may relate to business prospects are forward-looking statements. Actual results might differ materially from these statements due to risks and uncertainties, including the impact of competitive products and pricing, market acceptance of new products, market conditions and enforcement of intellectual property rights. A more detailed description of these risks and other risks applicable to Cepheid appears in Cepheid's reports filed with the U.S. Securities and Exchange Commission and available upon request from Cepheid. Cepheid disclaims any intent or obligation to update these forward-looking statements.